Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P, Sangsuwannukul T, Supimon K, Thuwajit C, Chieochansin T, Sa-Nguanraksa D, Samarnthai N, O-Charoenrat P, Junking M, Yenchitsomanus PT. Luangwattananun P, et al. Among authors: chieochansin t. Int Immunopharmacol. 2023 Nov;124(Pt B):111012. doi: 10.1016/j.intimp.2023.111012. Epub 2023 Oct 5. Int Immunopharmacol. 2023. PMID: 37804657
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.
Yuti P, Wutti-In Y, Sawasdee N, Kongkhla K, Phanthaphol N, Choomee K, Chieochansin T, Panya A, Junking M, Yenchitsomanus PT, Sujjitjoon J. Yuti P, et al. Among authors: chieochansin t. Int Immunopharmacol. 2022 Dec;113(Pt B):109442. doi: 10.1016/j.intimp.2022.109442. Epub 2022 Nov 23. Int Immunopharmacol. 2022. PMID: 36435066 Free article.
Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells.
Jirapongwattana N, Thongchot S, Chiraphapphaiboon W, Chieochansin T, Sa-Nguanraksa D, Warnnissorn M, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Jirapongwattana N, et al. Among authors: chieochansin t. Oncol Rep. 2022 Jul;48(1):127. doi: 10.3892/or.2022.8338. Epub 2022 May 26. Oncol Rep. 2022. PMID: 35616135 Free PMC article.
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Wathikthinnakon M, Luangwattananun P, Sawasdee N, Chiawpanit C, Lee VS, Nimmanpipug P, Tragoolpua Y, Rotarayanont S, Sangsuwannukul T, Phanthaphol N, Wutti-In Y, Somboonpatarakun C, Chieochansin T, Junking M, Sujjitjoon J, Yenchitsomanus PT, Panya A. Wathikthinnakon M, et al. Among authors: chieochansin t. Sci Rep. 2022 Apr 13;12(1):6154. doi: 10.1038/s41598-022-09964-6. Sci Rep. 2022. PMID: 35418130 Free PMC article.
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.
Wutti-In Y, Sujjitjoon J, Sawasdee N, Panya A, Kongkla K, Yuti P, Yongpitakwattana P, Thepmalee C, Junking M, Chieochansin T, Poungvarin N, Yamabhai M, Yenchitsomanus PT. Wutti-In Y, et al. Among authors: chieochansin t. Front Oncol. 2022 Jan 18;11:802876. doi: 10.3389/fonc.2021.802876. eCollection 2021. Front Oncol. 2022. PMID: 35117999 Free PMC article.
59 results